INS and Hypoglycemia: Hypoglycemia and cholelithiasis were more common in patients randomized to insulin than to incretin-based therapy (20.9% vs 10.5% and 16.3% vs 13.2%, respectively), whereas a greater proportion of patients in the incretin-based therapy group experienced decreased weight (23.7% vs 7.0%) and nausea (18.4% vs 4.7%) than in the insulin group.